Enzyme Replacement Therapy With Elosulfase Alfa Decreases Storage of Glycosaminoglycan in White Blood Cells of Patients With Morquio A Syndrome

Enzyme Replacement Therapy With Elosulfase Alfa Decreases Storage of Glycosaminoglycan in White Blood Cells of Patients With Morquio A Syndrome

Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by a deficient N-acetylgalactosamine-6-sulfate sulfatase activity, leading to cellular storage of undegraded keratan sulfate. Recently enzyme replacement therapy (ERT) was approved for MPS IVA, but some of...

Full description

Bibliographic Details
Main Authors:	Guilherme Baldo PhD, Fabiano Poswar MD, Andressa Federhen MSc, Camila Bittar MD, Rejane Gus PhD, Fernanda Bender MSc, Roberto Giugliani MD, PhD
Format:	Article
Language:	English
Published:	SciELO 2015-02-01
Series:	Journal of Inborn Errors of Metabolism and Screening
Online Access:	https://doi.org/10.1177/2326409814567741

Similar Items

Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome
by: Lee CL, et al.
Published: (2022-01-01)

Impact of Elosulfase Alfa on Pain in Patients with Morquio A Syndrome over 52 Weeks
by: Marsha Treadwell, et al.
Published: (2017-07-01)

Safety and Efficacy of Elosulfase Alfa in Australian Patients with Morquio a Syndrome: A Phase 3b Study
by: Kaustuv Bhattacharya, et al.
Published: (2020-05-01)

Role of elosulfase alfa in mucopolysaccharidosis IVA
by: Regier DS, et al.
Published: (2016-06-01)

Elosulfase alfa for mucopolysaccharidosis type IVA: Real-world experience in 7 patients from the Spanish Morquio-A early access program
by: Guillem Pintos-Morell, et al.
Published: (2018-06-01)

Elosulfase alfa enzyme replacement therapy attenuates disease progression in a non-ambulatory Japanese patient with Morquio A syndrome (case report)
by: Misako Hiramatsu, et al.
Published: (2017-12-01)

Relationship Between Patient-Reported Outcomes and Clinical Outcomes in Patients With Morquio A Syndrome
by: Christina Lampe MD, et al.
Published: (2015-04-01)

Abstract: Differential Osteogenic Signaling Pathways in Human Mesenchymal Stem Cells on Collagen Glycosaminoglycan Scaffolds
by: Justine C. Lee, MD, PhD, et al.
Published: (2017-09-01)

Abstract: Osteoprotegerin-Mediated Osteoclast Inhibition Is Augmented on Nanoparticulate Mineralized Collagen Glycosaminoglycan Materials
by: Justine C. Lee, MD, PhD, et al.
Published: (2018-09-01)

Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism
by: Bulent Kantarcioglu MD, et al.
Published: (2022-06-01)

22. The Role of Orai1 in Osteogenic Differentiation Induced by Nanoparticulate Mineralized Collagen Glycosaminoglycan Materials
by: Meiwand Bedar, MD, MSc, et al.
Published: (2023-05-01)

The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients
by: Bulent Kantarcioglu MD, et al.
Published: (2022-04-01)

Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis
by: Chung-Lin Lee, et al.
Published: (2022-08-01)

Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement
by: Bob Stevens, et al.
Published: (2021-09-01)

Pulmonary and intracranial miliary tuberculosis secondary to Behçet's anti-TNF alfa treatment
by: Asmae Sekkat, MD, et al.
Published: (2021-02-01)

Urinary Glycosaminoglycan Electrophoresis With Optimized Keratan Sulfate Separation Using Peltier System for the Screening of Mucopolysaccharidoses
by: Mihriban Tijen Tanyalcin MD, PhD
Published: (2015-10-01)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-12-01)

Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment—A Cohort Study Using a Postmarketing Surveillance Database
by: Seki Yoshinobu MD, PhD, et al.
Published: (2021-12-01)

192. Dynamic Changes In Temporospatial Phosphate Equilibrium By Nanoparticulate Mineralized Collagen Glycosaminoglycan Materials Induces Osteogenesis Via Pit-1 And Pit-2
by: Xiaoyan Ren, MD, PhD, et al.
Published: (2023-05-01)

Risk Factors Affecting Decreased Libido Among Middle-Aged to Elderly Men; Nocturnal Voiding is an Independent Risk Factor of Decreased Libido
by: Kazuyoshi Shigehara, MD, PhD, et al.
Published: (2021-10-01)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
by: Joseph Lewis BA, et al.
Published: (2022-05-01)

Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
by: Seung Hoon Lee, et al.
Published: (2022-06-01)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-01-01)

Shorter birth length and decreased T-cell production and function predict severe infections in children with non–severe combined immunodeficiency cartilage–hair hypoplasia
by: Eetu Pello, MD, et al.
Published: (2024-02-01)

Endogenous Glycosaminoglycans in Various Pathologic Plasma Samples as Measured by a Fluorescent Quenching Method
by: Bulent Kantarcioglu MD, et al.
Published: (2022-12-01)

Arthroscopic Hip Capsular Repair Improves Patient-Reported Outcome Measures and Is Associated With a Decreased Risk of Revision Surgery and Conversion to Total Hip Arthroplasty
by: Soshi Uchida, M.D., Ph.D., et al.
Published: (2023-12-01)

Revascularization of Peripheral Arteries in Patients with Intermittent Claudication Decreases Inflammatory Biomarkers
by: Pavel Poredoš MD, PhD, et al.
Published: (2023-06-01)

Inhibition of the Wnt Pathway Reduces Activation of the YAP/TAZ Mechanotransduction Pathways and Osteogenic Differentiation in Nanoparticulate Mineralized Collagen Glycosaminoglycan Materials
by: Michelle Oberoi, BS, BA, et al.
Published: (2021-10-01)

Abstract QS31: Calcium And Phosphate Ion Signaling Triggers Osteogenic Differentiation On Nanoparticulate Mineralized Collagen Glycosaminoglycan Scaffolds
by: Allison C. Hu, BA, et al.
Published: (2020-04-01)

Decreasing the Adverse Effects in Pelvic Radiation Therapy: A Randomized Controlled Trial Evaluating the Use of Probiotics
by: Irini Lazou Ahrén, PhD, et al.
Published: (2023-01-01)

The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients
by: Madeline Allen BS, et al.
Published: (2023-04-01)

Multiple Thrombi during Microvascular Anastomosis Caused by Decreased Antithrombin Activity: A Case Report
by: Takafumi Uchibori, MD, PhD, et al.
Published: (2020-06-01)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
by: Siddharth Mehrotra, et al.
Published: (2022-12-01)

Outcomes of a Physician Survey on the Type, Progression, Assessment, and Treatment of Neurological Disease in Mucopolysaccharidoses
by: Maurizio Scarpa MD, PhD, et al.
Published: (2018-03-01)

Special Issue Dedicated to the 13th ICIEM (Rio de Janeiro, Brazil, September 5-8, 2017)
by: Roberto Giugliani MD, PhD
Published: (2018-08-01)

The prevalence of hereditary angioedema in a Chinese cohort with decreased complement 4 levels
by: Qi Cui, MD, et al.
Published: (2022-01-01)

Abstract: Multiple Anastomotic Thrombus Due to Decreased Anti-Thrombin Activity during Microvascular Anastomosis - Case Report
by: Takafumi Uchibori, MD, PhD, et al.
Published: (2018-09-01)

Uninterrupted dabigatran is safer than warfarin in patients undergoing ablation for atrial fibrillation
by: Michael Spartalis, MD, MSc, PhD, et al.
Published: (2017-12-01)

VEGF Inhibition Associates With Decreased Risk of Mortality in Patients With Neovascular Age-related Macular Degeneration
by: Benjamin Sommer Thinggaard, MD, et al.
Published: (2024-05-01)

Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach
by: Michail Nikolaou MD, MSc, PhD, et al.
Published: (2019-01-01)